Last month, ‘Soliris (eculizumab)’ and ‘Ultromiris (ravulizumab),’ which both require prior approval to be administered with reimbursement, saw mixed results in the rate of approval of their preliminary applications.

In July, the Health Insurance Review and Assessment Service’s Healthcare Review and Assessment Committee deliberated reimbursement applications for Soliris, Ultomiris, ‘Spinraza inj. (nusinersen),’ ‘Strensiq inj.,’ and hematopoietic stem cell transplantation.

Deliberation results that were released on the 3rd showed that 3 new applications were filed for Soliris for its atypical hemolytic uremic syndrome indication but were denied. For Ultomiris, 40 of the 4